Related Experiment Video
Updated: Apr 12, 2026
09:16
A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
Published on: January 22, 2016
16.0K
Ibudilast reverses the decrease in the synaptic signaling protein phosphatidylethanolamine-binding protein 1 (PEBP1)
Sergios Charntikov1, Steven T Pittenger1, Ishwor Thapa2
1Department of Psychology, University of Nebraska-Lincoln, Lincoln, NE, USA.
Drug and Alcohol Dependence
|May 13, 2015
Summary
Ibudilast treatment reduced methamphetamine-seeking behaviors in rats by restoring synaptic protein PEBP1 levels and inhibiting the MAPK signaling pathway, offering a potential therapeutic strategy for addiction.
Area of Science:
- Neuroscience
- Pharmacology
- Molecular Biology
Background:
- Chronic methamphetamine use causes neuroinflammation and persistent behavioral changes, increasing relapse risk.
- Understanding these inflammation responses is crucial for developing effective addiction treatments.
Purpose of the Study:
- To investigate the effects of ibudilast on methamphetamine-induced neuroinflammation and associated behavioral changes.
- To identify molecular targets involved in methamphetamine addiction and relapse.
Main Methods:
- Rats self-administered methamphetamine or saline, followed by an extinction period with ibudilast or saline treatment.
- Synaptosomes from the prefrontal cortex were analyzed using mass spectrometry-based proteomics to assess synaptic protein changes.
Main Results:
- Ibudilast treatment led to deeper extinction of methamphetamine-seeking behavior.
- Methamphetamine intake reduced phosphatidylethanolamine-binding protein 1 (PEBP1) levels, which ibudilast reversed.
- Decreased PEBP1 correlated with activation of the MAPK pathway (Raf-1, MEK, ERK), which was also attenuated by ibudilast.
Conclusions:
- PEBP1 is a potential therapeutic target for drug-seeking behaviors linked to neuroinflammation.
- Ibudilast's modulation of PEBP1 and MAPK signaling may underlie its therapeutic effects in methamphetamine addiction.
More Related Videos
Related Concept Videos
01:20Desensitization and Tachyphylaxis
3.5K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
3.5K
01:29Drugs Affecting Neurotransmitter Synthesis
2.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.6K
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.9K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.9K